HC Wainwright Reaffirms Buy Rating for Kymera Therapeutics (NASDAQ:KYMR)

HC Wainwright reiterated their buy rating on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a research note published on Friday morning, Benzinga reports. They currently have a $46.00 target price on the stock. Several other analysts have also recently weighed in on KYMR. JPMorgan Chase & Co. raised their target price on shares […]

Related Keywords

Stifel Nicolaus ,Comerica Bank ,Principal Financial Group Inc ,Jpmorgan Chase Co ,Venture Fund Xlp Atlas ,Mirae Asset Global Investments Co ,Kymera Therapeutics Company Profile ,Wolfe Research ,Congress Asset Management Co ,Kymera Therapeutics Inc ,Ameritas Investment Partners Inc ,Kymera Therapeutics ,Free Report ,Moderate Buy ,Get Free Report ,Director Bruce Booth ,Venture Fund ,Investment Partners ,Asset Global Investments ,Asset Management ,Principal Financial Group ,Financial Group ,Kymera Therapeutics Daily ,